Exposure– and Dose–response Analyses in Dose Selection and Labeling of FDA-approved Biologics-Reference-Cited by-同舟云学术

Exposure– and Dose–response Analyses in Dose Selection and Labeling of FDA-approved Biologics

Published:2018-01 Issue:1 Volume:40 Page:95-102.e2
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Ogasawara Ken,Breder Christopher D.,Lin Dora H.,Alexander G. Caleb

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference23 articles.

1. IMS Institute for Healthcare Informatics. The global use of medicines: outlook through 2017. November 2013. www.imshealth.com/en/thought-leadership/ims-institute/reports/global-use-of-medicines-outlook-through-2017. Accessed September 17, 2017.

2. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012;Sacks;JAMA,2014

3. A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities;Lu;Cancer Chemother Pharmacol,2016

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Drug Postmarketing Requirements and Commitments in the US: A Systematic Review of the Evidence;Drug Safety;2022-02-19

2. Biotechnology-Derived Biologics Drug Products: Elimination;The ADME Encyclopedia;2022

3. Distribution of Biotechnology-Derived Biologics Drug Products;The ADME Encyclopedia;2022

4. A Semimechanistic Model of the Bactericidal Activity of High-Dose Isoniazid against Multidrug-Resistant Tuberculosis: Results from a Randomized Clinical Trial;American Journal of Respiratory and Critical Care Medicine;2021-12-01

5. Retrospective evaluation of appropriate dosing of cefmetazole for invasive urinary tract infection due to extended-spectrum β-lactamase-producing Escherichia coli;Journal of Infection and Chemotherapy;2021-11